The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
CM Wheeler, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Future II Study Group - The Journal of infectious diseases, 2007 - academic.oup.com
Abstract Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV)
L1 virus-like-particle (VLP) vaccine has been shown to be 95%–100% effective in …
L1 virus-like-particle (VLP) vaccine has been shown to be 95%–100% effective in …
Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses
LE Markowitz, AL Naleway, NP Klein… - The Journal of …, 2020 - academic.oup.com
Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo …
LL Villa, RLR Costa, CA Petta, RP Andrade… - The lancet …, 2005 - thelancet.com
Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
AR Giuliano, E Lazcano-Ponce, L Villa… - The Journal of …, 2007 - academic.oup.com
Abstract Background. The quadrivalent (types 6, 11, 16, and 18) human papillomavirus
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries
SM Garland, P Pitisuttithum, HYS Ngan… - The Journal of …, 2018 - academic.oup.com
Background A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine
extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical …
extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical …
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial
A Hildesheim, R Herrero, S Wacholder, AC Rodriguez… - Jama, 2007 - jamanetwork.com
ContextViruslike particle human papillomavirus (HPV) vaccines were designed to prevent
HPV infection and development of cervical precancers and cancer. Women with oncogenic …
HPV infection and development of cervical precancers and cancer. Women with oncogenic …
相关搜索
- young women particle vaccine
- hpv infection papillomavirus vaccine
- human papillomavirus particle vaccine
- human papillomavirus preexisting infection
- preexisting infection particle vaccine
- human papillomavirus young women
- human papillomavirus prophylactic efficacy
- preexisting infection young women
- hpv infection prophylactic efficacy
- hpv infection virological evidence
- human papillomavirus virological evidence
- human papillomavirus baseline covariates
- hpv infection human papillomavirus
- prevention of infection particle vaccine
- prevention of infection young women